Unmet Needs in HER2+ Early Breast Cancer
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss unmet needs in the treatment of patients with HER2-positive early breast cancer.
EP: 1.Prognosis and Survival Outcomes for HER2+ Early Breast Cancer
EP: 2.Evolving and Current Standards of Care for HER2+ Early Breast Cancer
EP: 3.AE Management With Neratinib in HER2+ Early Breast Cancer
Now Viewing
EP: 4.Unmet Needs in HER2+ Early Breast Cancer
EP: 5.Clinical Benefits With Neratinib in HER2+ Early Breast Cancer
EP: 6.Ongoing Research Efforts in HER2+ Early Breast Cancer
Related Videos
Related Content
